US Stock Market Move | Biopharmaceutical company Maplight Therapeutics (MPLT.US) listed on the US stock market, with its stock price rising more than 15.8%.

On Monday, the biopharmaceutical company Maplight Therapeutics (MPLT.US) made its debut on the US stock market, and as of the time of this report, the stock rose over 15.8% to $19.7. The IPO price was $17. MapLight was founded by internationally renowned leaders in psychiatry and neuroscience research, aiming to address the lack of drug therapy targeting specific neural circuits in patients. MapLight claims that its platform can identify neural circuits causally related to diseases and regulate treatment for these circuits. The company has developed a range of candidate products for treating some of the most challenging central nervous system diseases, such as schizophrenia, Alzheimer's disease, and autism spectrum disorders.